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A balanced and varied diet is the best source of essential vitamins and minerals; however, nutrient deficiencies
occur, including in populations with bountiful food supplies and the means to procure nutrient-rich foods. For
example, the typical American diet bears little resemblance to what experts recommend for fruit, vegetables, and
whole grains, which serve as important sources of an array of vitamins and minerals. With time, deficiencies in one
or more micronutrients may lead to serious health issues. A common reason people take multivitamin and mineral
(MVM) supplements is to maintain or improve health, but research examining the effectiveness of MVMs in the
prevention of certain chronic conditions is ongoing. In addition to the utility of MVMs for filling in relatively small
but critical nutritional gaps, which may help prevent conditions such as anemia, neural tube defects, and osteoporosis,
some evidence supports possible benefits of MVM supplementation with regard to cancer prevention (particularly in
men) and prevention or delay of cataract, as well as some aspects of cognitive performance. Unlike some single-
vitamin supplements, MVM supplements are generally well tolerated and do not appear to increase the risk of
mortality, cerebrovascular disease, or heart failure. The potential benefits of MVM supplements likely outweigh any risk
in the general population and may be particularly beneficial for older people.
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Evidence suggests that eating patterns that include rela-
tively high intakes of fruit, vegetables, nuts, and whole
grains are linked to a significantly lower risk of heart dis-
ease, cancer, and stroke [1,2], conditions that rank among
the top 4 leading causes of death in adults living in the
United States [3]. Plant foods, lean protein foods, and
low-fat dairy products are all important sources of micro-
nutrients that help ensure health and prevent disease [4].
The US Food and Nutrition Board of the Institute of
Medicine (IOM) has defined Dietary Reference Intakes
(DRI) for 29 vitamins and minerals (Table 1) [5]. Expert
groups including the Academy of Nutrition and Dietetics
(AND) recommend obtaining essential micronutrients
by eating a balanced and varied diet [6]. However, per-
sistent or periodic nutritional gaps are common in the
general population [7], and people who don’t consume
adequate amounts of certain foods may have nutrient
shortfalls. In addition, there are times throughout the life
cycle when the body requires more nutrients than theCorrespondence: eward@ix.netcom.com
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unless otherwise stated.typical diet may provide, such as iron during pregnancy
and vitamin B12 after age 50 years [4]. Over the course
of a lifetime, deficiencies in one or more nutrients may
contribute to serious health issues [8].
Dietary supplement use is common among consumers;
in the National Health and Nutrition Examination
Survey (NHANES), approximately half of all non-
institutionalized civilian persons living in the United
States were taking dietary supplements, most commonly
multivitamin and mineral (MVM) supplements, for a
variety of reasons [9,10]. Thirty-three percent to 39% of
the total US population takes multivitamins [9,11]. In
spite of their popularity, there is no standardized or
regulatory definition for MVM supplements. A range of
definitions have been used to describe MVMs, and the
term "MVM" may refer to products of widely varied
compositions and characteristics [12]. The US National
Institutes of Health has defined MVMs as supplements
that consist of 3 or more micronutrients at doses less
than the Tolerable Upper Level (UL) determined by the
Food and Nutrition Board of the IOM and are free of
herbs, hormones, or drugs [13]. Other definitions suggestis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Dietary reference intakes (DRIs): recommended
dietary allowances or adequate intakes for vitamins and
elements [5]
Micronutrient RDAs (bold) or AI (plain type) for adults
VITAMINS
Vitamin A 700–900 μg/d
Vitamin C 75–90 mg/d
Vitamin D 15–20 μg/d
Vitamin E 15 mg/d




Vitamin B6 1.3–1.7 mg/d
Folate 400 μg/d
Vitamin B12 2.4 μg/d
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vitamins [14,15]. Using these definitions, products with
widely varying compositions, ranging from those that
contain a small number of vitamins or minerals to those
containing many more vitamins and minerals, and in
varying doses, are all classified as MVM supplements.
This article reviews the potential health benefits and
risks of MVM supplements in several key areas, includ-
ing cancer, cardiovascular disease, age-related eye dis-
ease, and cognition. Although the focus of the article is
on MVM supplements containing 10 or more vitamins
and minerals, there have been relatively few studies,
such as the Physicians’ Health Study II (PHS II) [16,17],of such formulations. Most studies have investigated
individual vitamins, or MVMs with only a few constitu-
ents; such studies are reviewed here as appropriate.
Ensuring nutritional adequacy
Micronutrients are required for nearly all metabolic and
developmental bodily processes. The 2010 Dietary
Guidelines for Americans (DGA), issued by the US De-
partment of Agriculture and US Department of Health
and Human Services, recommend that “nutrient needs
should be met primarily through consuming foods”, but
also indicate that “in certain cases, fortified foods and
dietary supplements may be useful in providing one or
more nutrients that otherwise might be consumed in less
than recommended amounts” [4]. The DGA cites 4
nutrients of concern in adults and children living in the
United States: potassium, fiber, calcium, and vitamin D.
These nutrients are routinely underconsumed in the
general population. The DGA also recognizes folic acid,
iron, and vitamin B12 as nutrients of concern in certain
populations; folic acid and iron in women of childbear-
ing age, and vitamin B12 in men and women over the
age of 50 years [4].
The term “hidden hunger” has been used to describe
nutritional deficiencies that occur when people consume
adequate calories but inadequate micronutrients. “Hidden
hunger” is largely due to eating patterns dominated by
energy-dense, but nutrient-poor, foods that are often rela-
tively inexpensive [18]. Large nationally representative
surveys indicate that the intake of certain nutrients in the
US falls below the IOM’s Estimated Average Requirement
(EAR)—the average daily nutrient intake level estimated
to meet the requirements of half the healthy individuals in
a particular life stage and gender group [19]. For example,
in an analysis of data from NHANES for 2003 through
2006, the population had total usual intakes from all food
sources (excluding supplements) below the EAR for vita-
mins A, C, D, and E (45%, 37%, 93%, 91%, respectively),
calcium (49%), and magnesium (55%) [20].
Some people are at risk of micronutrient deficiencies
due to excessive losses (e.g., through hemodialysis), abnor-
mal metabolism (e.g., genetic polymorphisms, alcoholism,
conditions that impair fat absorption), and/or inadequate
synthesis (e.g., insufficient sunlight exposure to allow vita-
min D synthesis) [21]. Inadequate micronutrient intake,
sometimes even at borderline levels of deficiency, has been
linked to stunted growth and neurocognitive deficits [18],
as well as increased risks of various symptoms and condi-
tions [8,21-23]. Most nutrients act in all tissues, and all
tissues need all nutrients; therefore, inadequate intakes
may adversely affect every body system, but with more
pronounced effects in some than others [24].
Although MVM supplement formulations vary widely
in number of nutrients; dose of each; and the type, form,
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often instrumental in filling nutritional gaps [7], includ-
ing in populations where the food supply is relatively
bountiful and balanced [7,25-28]. In most cases, MVM
supplements lack potassium and provide far less than
the recommended daily intake for calcium, but many
MVMs provide adequate folic acid, iron, vitamin B12,
and vitamin D that can help prevent anemia, neural tube
defects, and bone disease [29]. For example, in general,
MVMs provide 100% of the daily value (a simplified refer-
ence value established by the US Food and Drug Adminis-
tration to facilitate label comparisons of the nutrient
content of food products [30]) for vitamin D [4], which is
useful for people who consume inadequate amounts of
vitamin D-rich foods, such as salmon, fortified milk, and
orange juice [4].
MVM supplements are what the name implies and
should not be regarded as substitutes for a balanced diet
and other beneficial lifestyle habits [8]. It is worth noting
that nutritional inadequacies are less common among
those who take MVM supplements, not only because of
the nutrients that MVMs provide, but also possibly be-
cause MVM supplement users may eat more nutrient-rich
foods and may have healthier lifestyles overall [31]. Data
from NHANES found that men, women, and children
who used MVM supplements had higher dietary intake of
key micronutrients than nonusers [7,32]. In another
national US study, regular use of supplements resulted in
an estimated ≥75% decrease in the proportion of older
persons with inadequate micronutrient intakes [25].
Prevention of chronic diseases
As defined by the Dietary Supplement Health and
Education Act of 1994 [33], dietary supplements are
intended to supplement the diet—not prevent or treat
disease. Yet, according to a recent national survey of US
residents, just 22% of dietary supplement users said they
take supplements “to supplement the diet” [10]. Among
the most common reasons people cited for using dietary
supplements were to “improve overall health” and to
“maintain health” [10]. The potential benefits of MVM
supplements in preventing certain chronic conditions
are not well established, but insight into the issue con-
tinues to emerge. When evaluating results across differ-
ent studies of supplementation with different MVM
formulations, it is important to note that MVM products
are not homogeneous [29]. The different types and
amounts of nutrients in the products available, as well as
differences in the duration of supplement use make it
challenging to compare across studies.
Cancer
The studies evaluating the effects of individual or small
combinations of vitamin and mineral supplements oncancer risk are inconsistent [34-40], and some trials and
meta-analyses have suggested an increased incidence of
cancer associated with certain individual vitamin sup-
plements. Although β-carotene and lutein are phytonu-
trients rather than vitamins, their long-term use, as well
as long-term retinol use, has been associated with an in-
creased risk of lung cancer, particularly in those at high
risk [41-43]. The randomized Selenium and Vitamin E
Cancer Prevention Trial (SELECT) reported that high-
dosage vitamin E supplementation was associated with a
17% increased risk of prostate cancer in healthy men
after 7 years (P = .008) [44]. A meta-analysis of 6 ran-
domized, controlled trials (RCTs) of folic acid supple-
mentation reported a possible increased risk of any
cancer [45], although another meta-analysis found folic
acid supplementation to be associated with 40% to 50%
reductions in risks of esophageal, gastric, and pancreatic
cancers [46]. Investigations of the effects of folate on
colorectal cancer risk have had conflicting results, with
protective effects shown for dietary folate and effects
ranging from modestly protective to potentially harmful
associated with supplementation with folic acid (the
synthetic form of folate) [47-52].
While findings on the effect of individual or small
combination supplements on cancer risk have showed
mixed results, some evidence from RCTs suggests a
benefit. The French Supplémentation en Vitamines et
Minéraux Antioxydants (SU.VI.MAX) RCT evaluated a
supplement containing ascorbic acid 120 mg, vitamin E
30 mg, β-carotene 6 mg, selenium 100 µg, and zinc
20 mg. This supplement was associated with a 31%
reduction in overall cancer incidence (P = .008) and a
37% reduction in overall mortality (P = .02) in men (ages
45–60 years), but not in women (ages 35–60 years), after
a median intake of about 7.5 years [53].
Two randomized, double-blind clinical trials evaluat-
ing the effects of MVM supplements on cancer risk were
conducted in rural Linxian County, China, which has a
relatively high rate of esophageal cancer and related
mortality, as well as a high rate of borderline deficiencies
in micronutrient intake [54]. One of the Linxian trials,
conducted in relatively healthy persons, found that sup-
plementation with a combination of β-carotene 15 mg/d,
vitamin E 30 mg/d, and selenium 50 μg/d for 5 years
was associated with a trend toward a 7% lower risk of
cancer and significant reductions in mortality (9% over-
all; 13% cancer specific) [54]. Long-term follow-up of
this study indicated that the benefits of taking MVMs
persisted for up to 10 years after active supplementation
had ceased [55]. The second Linxian study compared
Centrum® multivitamins (Pfizer Consumer Healthcare,
Madison, NJ) (2 pills daily containing 26 vitamins and
minerals) plus 15 mg/d β-carotene versus placebo for
6 years in 3,318 patients with esophageal dysplasia and
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did not reduce or increase the incidence of any cancer,
including esophageal/gastric cancers, although there were
nonsignificant trends favoring supplementation with re-
gard to overall and cancer-specific mortality.
The recent PHS II was a large (N = 14,641), long-term
(median 11.2 years follow-up) RCT of the MVM
Centrum® Silver (Pfizer Consumer Healthcare) once
daily in male physicians in the United States [16]. MVM
supplementation was associated with a statistically
significant 8% reduction in incidence of total cancer
(P = .04; Figure 1). In addition, men with a history of can-
cer derived the most benefit from MVM supplementation,
with a 27% lower incidence of new cancer versus placebo
in this subgroup (P = .02). There was no effect on the risk
of any specific individual cancer types due to a lack of stat-
istical power, and there was a nonsignificant trend toward
lower cancer-specific mortality (P = .07). Because the study
was conducted with well-nourished male physicians, it is
not known whether the results apply to other types of
people, including women and those more likely to have
dietary insufficiencies.
Data from some meta-analyses and large nonrando-
mized trials of MVM supplement users also suggest a
possible protective effect against cancer. A meta-analysis
of 13 prospective European and North American cohort
studies reported a decrease in risk of colon cancer
among MVM supplement users compared with nonusers
(relative risk [RR]: 0.88; 95% confidence interval [CI]:
0.81–0.96) [57]. MVM supplement use for 15 years was
associated with a 75% reduction in colon cancer risk in
the prospective Nurses’ Health Study (NHS) based on
questionnaires completed by 88,756 female nurses in the
United States [51]. In another report from the NHS,
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Figure 1 Physicians' Health Study II cumulative incidence of
total cancer with MVM supplements vs placebo [16].breast cancer [58]. This study did, however, report an
increase in risk of non-Hodgkin’s lymphoma (6–9 multi-
vitamins/week: RR: 1.39; 95% CI: 1.05–1.83; ≥10 multivi-
tamins/week: RR: 3.36; 95% CI: 1.93–5.86; P for trend =
.0008), and risk was higher among women who used MVM
supplements for ≥10 years [59]. No such association was
found among men in the Health Professionals Follow-up
Study [59].
Overall, there is little evidence that MVM supplements
increase cancer risk. Analysis of data from a 1997 dietary
questionnaire administered to the Swedish Mammog-
raphy Cohort reported a 19% higher risk of breast
cancer among MVM supplement users versus nonusers
[60]. However, a subsequent meta-analysis of 5 cohort
studies (including the Swedish Mammography Cohort
study) and 3 case–control studies found that MVM sup-
plement use had no impact—positive or negative—on
the risk of breast cancer (cohort studies: RR: 0.99; 95%
CI: 0.60–1.60; case–control studies: odds ratio [OR]:
1.00; 95% CI: 0.51–1.97) [61]. Furthermore, the Women’s
Health Initiative, a large observational study, reported that
MVM supplement use was not associated with an increase
in risk of breast, colorectal, endometrial, ovarian, kidney,
bladder, stomach, or lung cancer in postmenopausal
women [62]. A meta-analysis of 4 RCTs, 8 cohort studies,
and 2 case–control studies found no association between
use of MVM supplements and prostate cancer (OR: 1.11;
95% CI: 0.95–1.29) [63]. As already discussed, an in-
creased risk of lung cancer and prostate cancer has been
observed in some trials employing levels of certain micro-
nutrients much higher than the RDA [41-45]. It is possible
that the increase in cancer seen in these studies is due to
the fact that high levels of individual vitamins may be
harmful and should be used with caution. This theory is il-
lustrated in SELECT, which found no association between
the combination of vitamin E and selenium and prostate
cancer (hazard ratio [HR]: 1.05; 99% CI: 0.89–1.22,
P = .46), even though vitamin E was associated with an
increased risk [44].
Although many of these earlier trials, including cohort
studies and trials of MVM supplements with fewer than
10 ingredients, have yielded mixed results in terms of
their impact on cancer incidence and mortality, PHS II
confirms the results from a range of trials that suggest a
benefit of dietary supplementation in cancer prevention,
at least in a population of well-nourished males in the
United States. PHS II was likely able to measure a pre-
vention benefit in cancer for a number of reasons.
Firstly, a multivitamin composed of most of the essential
vitamins and minerals was used, thus addressing all
potential nutritional inadequacies and providing appro-
priate balance to the different components of the multi-
vitamin [17], since it is possible that there are potential
risks associated with supplementation of single vitamins
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plementary vitamins/minerals [44]. Secondly, PHS II
employed a large population in a prospective, random-
ized, placebo-controlled trial and was powered to detect
differences in cancer incidence. Finally, subjects in PHS II
were followed for a relatively long period of time (mean of
11.2 years). As demonstrated in the NHS, long-term use
of continuous multivitamins for 10 to 15 years may be
required for the benefits to be realized [51].
Cardiovascular disease
There is minimal evidence that supplementation with in-
dividual micronutrients reduces cardiovascular disease
(CVD) risk. Research into potential cardiovascular bene-
fits of dietary supplements has focused particularly on B
vitamins because of their established correlation with
levels of homocysteine, a marker for CVD risk, including
ischemic stroke [64]. A meta-analysis of 19 RCTs of B
vitamins (including folic acid, vitamin B6, vitamin B12,
and B-complex vitamins) found no effect of supplemen-
tation on rates of CVD, coronary heart disease, myocar-
dial infarction (MI), cardiovascular death, or all-cause
mortality despite significant reductions in homocysteine
levels; however, risk of stroke was reduced by 12% (RR:
0.88; 95% CI: 0.82–0.95) [64]. A second meta-analysis of
26 RCTs of folic acid supplementation resulted in a 7%
reduction in risk of stroke (P = .05) [65]. Supplementa-
tion with vitamin E, β-carotene, and vitamin C, a group
of vitamins sometimes referred to as antioxidant vita-
mins, has had similarly neutral results with regard to
cardiovascular outcomes. A meta-analysis of 15 RCTs
found that supplementation with vitamin E, β-carotene,
and vitamin C had no effect on rates of major cardiovas-
cular events, MI, stroke, overall or cardiovascular mor-
tality, revascularization, coronary heart disease, angina,
or congestive heart failure [66].
The double-blind, randomized, placebo-controlled Heart
Outcomes Prevention Evaluation (HOPE) and 7-year
open-label HOPE-The Ongoing Outcomes extension
found significant increases in risk of heart failure (P = .03)
and related hospitalization (P = .045) associated with vita-
min E supplementation (400 IU/d) in high-risk people
≥55 years of age [67]. A meta-analysis of 9 RCTs further
found vitamin E supplementation to be associated with a
significant 22% increase in risk of hemorrhagic stroke
(P = .045), but a 10% decrease in risk of ischemic stroke
(P = .02) [68].
A number of studies have investigated the effect of
MVM supplements on CVD risk. The randomized PHS
II study described above also evaluated the effects of
MVM supplementation on major cardiovascular events,
including nonfatal MI, nonfatal stroke, cardiovascular
mortality, total MI, total stroke, and congestive heart
failure and found no significant reduction in CVD risk[17]. Similar results were seen in the first PHS, in which
MVM supplements were not associated with any in-
creased or decreased risk of death from coronary heart
disease (P = .88) or CVD mortality (P = .46) in healthy
male physicians [69].
MVM supplements were associated with cardiovascular
benefits in the Stockholm Heart Epidemiology Program
(SHEEP), a large Swedish population-based case–control
study [70]. SHEEP compared adults aged 45 to 70 years
who had no previous history of MI with those who had
experienced a first MI and survived >28 days. Regular use
of dietary supplements, 80% of which were MVM supple-
ments, was associated with a significant 22% reduction in
risk of MI in men and a significant 33% reduction in risk
of MI in women compared with nonuse after controlling
for consumption of fruit, vegetables, and fiber. However, it
is difficult to draw conclusions as to the role of MVMs in
this study since their use was self-reported and the com-
position of MVMs and other supplements used may have
been somewhat variable.
The benefits of taking MVMs for women were also
seen in a separate population-based Swedish cohort
study (N = 38,984 women) in which use of MVM supple-
ments alone was associated with a 27% (95% CI: 7%–
43%) lower risk of MI compared with nonuse in women
ages 49 to 83 years with no history of CVD. MVM sup-
plement use for 5 years or longer was associated with a
further 41% (95% CI: 44%–80%) reduction in risk of MI.
However, MVM supplements had a neutral effect on risk
of MI in women with a history of CVD [71].
The Vitamin and Lifestyle Study, a population-based
prospective study, evaluated mortality in a cohort of
77,673 subjects from western Washington State who
used either MVM supplements (defined as containing 10
or more vitamins and/or minerals) or individual vitamin
C and E supplements [72]. There was no association be-
tween MVM supplement use and risk of total mortality
at any duration or frequency of use, nor were MVM
supplement users at a statistically significant higher risk
for death from CVD, cancer, or other causes. Use of
MVM supplements for 6 to 7 days per week for 10 years
was associated with a decrease in mortality due to CVD
among persons with no history of CVD (HR: 0.78; 95%
CI: 0.62–0.98).
Results of the studies reviewed here indicate that there
is little evidence that MVM supplements have a negative
impact on cardiovascular risk and that they may have a
modest benefit in certain groups of people.
Age-related eye disease
Studies of 1 or 2 vitamin supplements have not proven
benefit in preventing or slowing eye disease [73,74]. For
example, in a Swedish population-based cohort study of
men ages 45 to 79 years, use of high-dose vitamin C or
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dence of age-related cataract. However, use of multivita-
mins only or multiple supplements in addition to vitamin
C or E was not associated with cataract risk [73].
In the randomized Age-Related Eye Disease Study
(AREDS), over a median of 6.3 years, high doses of 3 vi-
tamins with antioxidant properties (500 mg/d vitamin C,
400 IU/d vitamin E, and 15 mg/d β-carotene) with zinc
(80 mg zinc oxide) significantly reduced the risk of pro-
gression to advanced age-related macular degeneration
(AMD) by 28% (P = .007) [75] and reduced the risk of
any lens opacity by 16% and of nuclear cataract by 25%
(both P < .01) [76]. In the AREDS2 RCT, the addition of
the carotenoid alcohol phytonutrients lutein (10 mg)
and zeaxanthin (2 mg), and omega-3 fatty acids, docosa-
hexaenoic acid (350 mg) and eicosapentaenoic acid
(650 mg) or all four to the original AREDS formulation
did not slow progression to advanced AMD or loss of
visual acuity in people aged 50 to 85 years at high risk of
progression to advanced AMD [77]. However, among
the two-thirds of participants in the original AREDS trial
who elected to take a formulation of Centrum® without
lutein, MVM supplementation resulted in a significant
reduction in development or progression of cataract
after a median follow-up of 6.3 years (OR: 0.88; 95% CI:
0.79–0.98) [76]. Furthermore, in the 1.5-year, multicen-
ter Age Related Macular Degeneration Study Group
study, OcuGuard® (Twinlab Corporation, American
Fork, UT), an MVM supplement containing 14 antioxi-
dants and minerals, stabilized multiple measures of
visual function (Logarithm of the Minimum Angle of
Resolution [LogMAR] activity, near M print acuity, and
6 cycle/degree contrast sensitivity in left eyes) in patients
with AMD [78].
The Italian-American Clinical Trial of Nutritional
Supplements and Age-Related Cataract (CTNS) was a
single-center RCT of MVM supplements (Centrum®) in
persons aged 55 to 75 years who had early cataracts (n =
710) or no cataracts (n = 310) [79]. After a mean follow-
up of 9 years, those who received MVM supplementation
were 18% less likely to experience a lens event, defined as
development or progression of any cataract (P = .03). Ana-
lysis of specific types of opacities indicated that MVM
supplements were associated with a 34% lower risk of nu-
clear opacity (P = .004), a neutral effect on cortical opacity
(P = .07), and a doubling in the risk of the less common
posterior subcapsular cataract opacity (P < .001).
Similar results were seen in the PHS II trial, which also
evaluated the effects of MVM supplements on eye dis-
ease in healthy male physicians [80]. This study showed
that daily supplementation with MVM supplements
significantly reduced the risk of total cataract by 9%
compared to placebo (P = .04) but had no effect on the
incidence of visually significant AMD [HR: 1.19; 95% CI:0.94–1.50; P = .15]). As with the Italian-American CTNS,
MVM supplements significantly reduced the risk of
nuclear cataract by 13% compared to those assigned to
placebo (P = .005). There were also 10% fewer cortical
cataracts with MVM, although this did not reach statis-
tical significance (P = .17). MVMs had no effect on the
development of posterior subcapsular cataract (P = .85).
It is evident from the studies discussed here that
MVM supplements have little effect on the prevention
or progression of AMD, with just 1 of 3 studies showing
only limited benefit [78]. However, it appears that they
can be taken safely in combination with the high-dose
antioxidant vitamins that have been shown to reduce the
rate of eye disease progression. All 4 of the studies that
investigated the effect of MVMs on cataract suggested
that MVM supplements have a role in the prevention of
cataract, particularly the most common subtype, nuclear
cataract.
Cognition
MVM supplementation has resulted in limited benefits
to cognitive performance in some, but not all, studies. A
meta-analysis of 10 RCTs (N = 3,200) concluded that
daily MVM supplement use by cognitively intact adults
significantly improved immediate free recall memory
(P < .01), with the strongest effect seen for MVM supple-
ments with more constituents, but that MVM supple-
ments had no significant effects on delayed free recall
memory or verbal fluency [14]. Two of the studies
reviewed suggested possible improvements in mathemat-
ical processing ability. One limitation of this analysis is
that 7 of the 10 trials studied MVM supplement use for
short durations ranging from 6 weeks to 6 months, so the
effects of longer MVM use on cognitive function are not
known.
In an RCT of healthy adults aged 18 to 86 years, a
supplement containing the vitamins folic acid (400 μg),
vitamin B12 (6 μg), and vitamin E (30 IU alpha-
tocopherol), as well as S-adenosylmethionine (400 mg),
N-acetyl cysteine (600 mg), and acetyl-L-carnitine
(500 mg) improved cognitive performance for the dur-
ation of its use only [81]. These latter compounds have a
range of physiologic roles in metabolism and are often
taken as supplements. Improvements were seen on some
parts of the California Verbal Learning Test II (which
measures short- and long-term word recall) and the
Trail-Making Test (a measure of neuromuscular coord-
ination and executive function) both in the double-blind
phase and in an open-label extension. Scores returned to
baseline following withdrawal of the supplement, but
improved again when the supplement was reintroduced.
An increased percentage of participants 74 years of age
or older did not show improvement with the supplement
product, which may be due to age-related difficulties in
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related cognitive decline during the course of the study.
The authors concluded that the findings from this par-
ticular study support the benefit of nutritional supple-
ments containing vitamins and other biologically active
compounds for cognitive performance and that the
elderly may require additional supplementation.
An RCT of an Australian supplement containing ap-
proximately 50 vitamins, minerals, and herbs found that
it improved contextual recognition memory in men aged
50 to 74 years [82]. Contextual recognition memory, a
measure of episodic memory, is often the first cognitive
function to be impaired in patients with progressive cog-
nitive decline or Alzheimer’s dementia. In a second
study, a version of the supplement designed for women
improved speed of response on a measure of spatial
working memory in women aged 64 to 82 years who
had reported memory worsening at screening [83].
The randomized, controlled Mineral and Vitamin
Intervention Study, conducted in North-East Scotland,
evaluated the cognitive effects of a daily MVM supple-
ment containing 16 vitamins and minerals in 910
persons age ≥65 years [84]. After 1 year, there was no
evidence of benefit on tests of immediate memory (digit
span forward test) and executive function (verbal fluency
test).
Evidence for cognitive benefits of MVMs is limited to
a small number of studies showing positive results with
only some of the cognitive tests performed. There have
been no reports of MVM supplements having a negative
impact on cognitive function, and it’s probably reason-
able to use MVMs to address nutritional gaps with little,
if any, concern for increasing the rate of cognitive
decline. However, it should be noted that older persons
have likely been exposed to dietary deficiencies for
longer periods of time and have nutritional status that is
less homogeneous than younger populations, com-
pounded by disease and polypharmacy. As a result, the
use of supplements is harder to generalize for popula-
tions over 60 years of age.
Mortality
Concerns have arisen, based on studies employing sup-
plements with individual or combinations of a small
number of vitamins, that dietary supplements may pos-
sibly be associated with increased mortality. In general,
data on the effects of MVM supplements on mortality
have been largely reassuring.
In the randomized PHS II study described above,
MVM supplementation trended positively, but did not
alter total mortality significantly (P = .13) [16]. Several
large observational studies have similarly shown no in-
crease in risk of mortality among MVM supplement
users [72,85,86], as did a meta-analysis of 21 RCTs (RR:0.98; 95% CI: 0.94–1.02) [15]. Similarly, the Multiethnic
Cohort Study of 215,000 ethnically diverse persons living
in Hawaii and California who completed a detailed ques-
tionnaire on diet, medical history, and lifestyle showed
no increase in risk among men or women who used
MVM supplements versus nonusers with regard to over-
all mortality or mortality attributable to CVD, cancer, or
all other causes during 11 years of follow-up [85]. The
single exception to those findings was in men who used
MVM supplements either more than once daily or for
<5 years’ duration who had a possible increase in risk of
mortality from causes other than CVD or cancer. A study
using nationally representative data from NHANES I
(N = 10,758) found no evidence that MVM supplements
affected mortality [86]. Overall mortality was compar-
able for regular users compared with nonusers among
men (RR: 0.94; 95% CI: 0.82–1.06) and women (RR:
1.02; 95% CI: 0.90–1.17).
One study with contrasting data was the Iowa Women’s
Health Study, a nonrandomized, observational trial in
postmenopausal women that showed a significant 6%
increase in mortality in women taking MVMs [87]. How-
ever, the Women’s Health Initiative observational trial,
conducted with a similar population of 161,806 postmeno-
pausal women, found no increase in risk of death over
8 years of follow-up among MVM supplement users (HR:
1.02; 95% CI: 0.97–1.07) [62]. Finally, a 5% increase in
mortality rate was found in men, but not women, who
self-reported use of MVM supplements as part of a large
(N = 1,063,023) observational US study [88]; however,
death rates were lower among both men and women if
they used a combination of MVM supplements and vita-
min A, C, or E. Overall, these studies suggest that gener-
ally well-nourished populations that take MVMs suffer no
significant increased risk of mortality. There are some
weaknesses in these analyses of mortality. Firstly, most of
these studies rely on self-report of MVM use, so it is not
clear if subjects were taking formulations that were age
and gender appropriate. Secondly, none of these studies
have investigated mortality in a cohort of patients who
took an MVM consistently starting at a young age, follow-
ing them over a lifetime.
Conclusions and implications for practice
MVMs may help prevent a number of health problems.
In bridging nutrient gaps, it is plausible that MVMs help
prevent iron-deficiency anemia, neural tube defects,
neurological damage in people age 50 years and older,
and bone disease by supplementing the diet with iron,
folic acid, vitamin B12, and vitamin D, respectively.
A recent draft of the US Preventive Services Task
Force found that there was no rationale to recommend
for or against multivitamin use for primary prevention
of CVD or cancer [89]. Although this group noted the
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SU.VI.MAX, the lack of generalizability to the general
population meant evidence was insufficient to recom-
mend routine use of MVM supplementation for primary
prevention. The group also noted little consistent
evidence to support or refute a role of single and paired
vitamins and minerals in the prevention of cancer. A
recent review by Comerford suggested that these more
recent studies provided moderate evidence suggesting
that MVM supplements containing vitamins and min-
erals at or near the Recommended Dietary Allowance
(RDA) are beneficial in reducing the risk of chronic dis-
ease in at-risk populations, especially given their demon-
strated safety [90].
It is necessary to consider a person’s medical history
as well as the quality of their diet when advising on the
use of MVMs. For example, for people with a history of
cancer, those taking prescription and over-the-counter
medications, and those planning surgery should consult
their doctors about taking MVMs and other dietary sup-
plements. Likewise, people who take MVMs and other
dietary supplements and who regularly consume fortified
foods and beverages may consume certain nutrients at
levels exceeding the IOM’s UL, which may cause adverse
effects.
Even when a diet is well planned, it is not always pos-
sible for most people to choose foods containing the rec-
ommended amounts of all essential micronutrients, and
chronic, relatively minor nutrient shortfalls can cause
health problems. The role of MVMs also needs to be
considered in the context of macro-nutrient consump-
tion (carbohydrates, protein, and fats) and its effects on
digestion, absorption, and bioavailability of vitamins and
minerals, as well as the effect of the balance of macro-
nutrient intake on metabolism and the need for different
vitamins and minerals. While MVM supplements cannot
replace eating adequate amounts of a variety of foods,
they may be particularly beneficial to people who have
poor nutrition for a variety of reasons, including
inadequate intake of foods from all the food groups,
advanced age, and chronic illness.
When choosing an MVM product, consumers should
take a preparation that is tailored to their age, gender,
family history/risk factors, and stage of life, including the
childbearing years and the senior years. Wherever pos-
sible, the specific MVM formulation selection should be
based on a nutritional assessment that identifies defi-
ciencies as well as inadequate or erratic intake that can
put a person at risk for deficiencies. The decision to take
an MVM, like the decision to take any drug or supple-
ment, should consider whether any potential risks out-
weigh the benefits. For example, smokers and, possibly,
former smokers should avoid MVMs with large amounts
of β-carotene or vitamin A, because studies have linkedthese nutrients to an increased risk of lung cancer in this
population [42,43]. Taking excess vitamin A (as pre-
formed retinol but not β-carotene) during pregnancy
can increase the risk of birth defects, so women capable
of conceiving should consider the advice to limit daily
consumption of preformed vitamin A to 10,000 IU/d
(3,000 μg/d) or less [91]. Likewise, the Centers for
Disease Control and Prevention recommends all women
capable of becoming pregnant take 400 μg folic acid
daily to help prevent birth defects [4]. Most healthy
adult males and postmenopausal women should also
avoid MVMs with more than 8 mg of iron and limit
their total iron intake to 45 mg/d [91].
When deciding whether to recommend the use of
dietary supplements, it is important to consider the
benefit:risk ratio. Current data suggest minimal, if any,
risk associated with MVM preparations containing 10 or
more vitamins and minerals at recommended daily in-
take levels in healthy people and a possibility of modest
benefits that include a reduced risk of cancer and nu-
clear cataract, for a relatively low financial cost.
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